Recurrent Osteosarcoma Clinical Trials

56 clinical trials for Recurrent Osteosarcoma across international registries, including 5 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Trastuzumab Deruxtecan (DS-8201a) for the Treatment of Recurrent or Refractory Osteosarcoma, Wilms Tumor, and Desmoplastic Small Round Cell Tumor — RECRUITING · PHASE1
• Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma — RECRUITING · PHASE1
• Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors — RECRUITING · PHASE1
• Atezolizumab and Cabozantinib for the Treatment of Adolescents and Young Adults With Recurrent or Metastatic Osteosarcoma, TACOS Study — RECRUITING · PHASE2
• Genetically Engineered Cells (FH-FOLR1 ST CAR T Cells) for the Treatment of Advanced Refractory or Recurrent/Progressive Osteosarcoma, FIERCe Trial — RECRUITING · PHASE1
• Humanized Monoclonal Antibody 3F8 (Hu3F8) With Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in the Treatment of Recurrent Osteosarcoma — ACTIVE_NOT_RECRUITING · PHASE2
• Testing a New Immune Cell Therapy, GD2-Targeted Modified T-cells (GD2CART), in Children, Adolescents, and Young Adults With Relapsed/Refractory Osteosarcoma and Neuroblastoma, GD2-CAR PERSIST Trial — SUSPENDED · PHASE1
• Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial — ACTIVE_NOT_RECRUITING · PHASE2
• Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) — ACTIVE_NOT_RECRUITING · PHASE2
• Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors — ACTIVE_NOT_RECRUITING · PHASE2
• Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial — ACTIVE_NOT_RECRUITING · PHASE2
• Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial) — ACTIVE_NOT_RECRUITING · PHASE2
• Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial) — ACTIVE_NOT_RECRUITING · PHASE2
• Testing the Combination of Two Immunotherapy Drugs (Magrolimab and Dinutuximab) in Patients With Relapsed or Refractory Neuroblastoma or Relapsed Osteosarcoma — TERMINATED · PHASE1
• Oleclumab and Durvalumab for the Treatment of Recurrent, Refractory, or Metastatic Sarcoma — ACTIVE_NOT_RECRUITING · PHASE2
• Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial) — ACTIVE_NOT_RECRUITING · PHASE2
• Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial) — ACTIVE_NOT_RECRUITING · PHASE2
• Cabozantinib S-malate in Treating Patients With Relapsed Osteosarcoma or Ewing Sarcoma — ACTIVE_NOT_RECRUITING · PHASE2
• LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas — ACTIVE_NOT_RECRUITING · PHASE2
• Gemcitabine, Docetaxel, and Hydroxychloroquine in Treating Participants With Recurrent or Refractory Osteosarcoma — ACTIVE_NOT_RECRUITING · PHASE1
• Single-Patient Expanded Access Protocol - RNA-LP in a Patient With Recurrent Osteosarcoma — TERMINATED
• Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial) — COMPLETED · PHASE2
• Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial) — COMPLETED · PHASE2
• Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial) — COMPLETED · PHASE2
• Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial) — COMPLETED · PHASE2
• Pepinemab in Treating Younger Patients With Recurrent, Relapsed, or Refractory Solid Tumors — COMPLETED · PHASE1
• IM83 Clinical Study of CAR-T Cell Therapy in Patients With Relapsed or Refractory Osteosarcoma — OTHER · PHASE1
• Denosumab in Treating Patients With Recurrent or Refractory Osteosarcoma — COMPLETED · PHASE2
• Dinutuximab in Combination With Sargramostim in Treating Patients With Recurrent Osteosarcoma — COMPLETED · PHASE2
• Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas — COMPLETED · PHASE1
• Adjuvant Therapy for High-risk Hepatocellular Carcinoma Post Liver Transplantation — NOT_YET_RECRUITING · PHASE2
• Registry For Children, Adolescents And Adults With Osteosarcoma And Biologically Related Bone Sarcomas — NOT_YET_RECRUITING
• Pazopanib Hydrochloride and Topotecan Hydrochloride in Treating Patients With Metastatic Soft Tissue and Bone Sarcomas — COMPLETED · PHASE2
• DNA Biomarkers in Tissue Samples From Patients With Osteosarcoma — COMPLETED
• Glembatumumab Vedotin in Treating Patients With Recurrent or Refractory Osteosarcoma — COMPLETED · PHASE2
• Eribulin Mesylate in Treating Patients With Recurrent or Refractory Osteosarcoma — COMPLETED · PHASE2
• Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia — COMPLETED · PHASE2
• Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma — COMPLETED · PHASE2
• Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma — COMPLETED · PHASE1
• Imetelstat Sodium in Treating Younger Patients With Relapsed or Refractory Solid Tumors — WITHDRAWN · PHASE2
• Therapeutic Angiotensin-(1-7) in Treating Patients With Metastatic Sarcoma That Cannot Be Removed By Surgery — COMPLETED · PHASE2
• Biomarker Expression in Tissue Samples From Patients With Bone Sarcomas — COMPLETED
• Study of Blood Samples From Patients With Osteosarcoma — COMPLETED
• Temsirolimus and Cixutumumab in Treating Patients With Locally Advanced, Metastatic, or Recurrent Soft Tissue Sarcoma or Bone Sarcoma — COMPLETED · PHASE2
• Biomarkers in Predicting Response to Chemotherapy in Samples From Young Patients With Osteosarcoma — COMPLETED
• Imatinib Mesylate in Treating Patients With Relapsed or Refractory Solid Tumors of Childhood — COMPLETED · PHASE2
• Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors — COMPLETED · PHASE2
• Ixabepilone in Treating Young Patients With Refractory Solid Tumors — COMPLETED · PHASE2
• Sorafenib in Treating Patients With Soft Tissue Sarcomas (Extremity Sarcoma Closed to Entry as of 5/30/07) — COMPLETED · PHASE2
• Flavopiridol in Treating Children With Relapsed or Refractory Solid Tumors or Lymphomas — COMPLETED · PHASE1

Refine this search